Either you do not have the newest version of Adobe Flash®, or you have JavaScript disabled.

Please ensure you have these capabilities.

RELEASES

  • For further information contact:
    Fred Iannotti
    802-888-0085
    fiannotti@planningsource.com

    4th Annual Oral Cancer Symposium at Tufts Offers Opportunity for Identafi™ 3000 Demo.

    World's First "Multispectral" Oral Cancer Detection Device Featured

    BOSTON, June 4, 2009 — The all-day-long 4th Annual Oral Cancer Symposium gets under way 9 AM tomorrow at Tufts University's School of Dental Medicine.

    On hand will be TRIMIRA LLC's Identafi™ 3000 oral cancer detection device — the world's most powerful and accurate screening tool for revealing signs of oral cancer and pre-cancer. Demonstrations of the device are available by appointment with TRIMIRA VP Jerry S. Trzeciak (cell: 281-793-3038), who is attending the event.

    Leading the event will be Dr. Michael A. Kahn, DDS, chair and professor of the Oral and Maxillofacial Department at Tufts University.

    4th Annual Oral Cancer Symposium:
    http://dental.tufts.edu/1186056455485/TUSDM-Page-dental2w_1230026403981.html

    Trzeciak noted that Identafi™ 3000 is a next-generation imaging tool that changes the diagnostic landscape. Designed for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians, Identafi™ 3000 enables the user to pinpoint biochemical and morphological changes in cells of the mouth, throat, tongue, and tonsils, and get real-time results.

    Oral cancer kills one person, every hour, every day.

    Oral cancer is typically detected by a doctor, not a dentist, by which time it is usually a late-stage diagnosis. In fact, 40 percent of those diagnosed with oral cancer will be dead in five years. Early detection of oral cancer would improve the survival rate to 80-90 percent. But fewer than 15 percent who visit a dentist get screened regularly.

    While tobacco and alcohol use are the traditional contributors to oral cancer, the new vector is sexual activity, notably oral sex, with HPV-16 and -18 implicated. HPV oral cancer lesions occur mainly in the back of the throat, base of the tongue, and tonsillar pillars. Hence the need for a device that reliably, inexpensively, quickly, and accurately detects cancer and pre-cancer that is not visible to the naked eye.

    "It is absolutely clear that traditional techniques of visual and tactile examination are inadequate," Trzeciak said. "What is also clear is that a new device delivering a new standard of care was needed. That device needs to incorporate the latest advances in detection, be affordable, portable, cordless, easy to use, and accurate. That device needs to dramatically reduce false positives. That device is Identafi™ 3000."

    Identafi™ 3000 is the first and only device to employ the new three-wavelength, or "multispectral," optical fluorescence and reflectance technology patented by TRIMIRA. Identafi™ 3000, which was developed in collaboration with research scientists at M.D. Anderson Cancer Center, Rice University, and British Columbia Cancer Research Center, is now available through U.S. distributors nationwide.

    Identafi 3000 is a quantum leap in the visualization of mucosal abnormalities, including oral cancer or premalignant dysplasia. The technology is diagnostic in screening for oral cancers but also will be applied to diagnose cervical, skin, bladder, and gastrointestinal cancers. Unlike other methods, Identafi 3000 empowers health professionals to pinpoint biochemical and morphological changes in cells.

    Houston-based TRIMIRA is venture capital-funded by Dallas-based long-time cancer research philanthropist T. Boone Pickens, of oil and windfarming fame.

    About TRIMIRA™ LLC

    TRIMIRA™ LLC is a subsidiary of Remicalm LLC, a privately held medical device and optical imaging company. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.

    Visit TRIMIRA™ at: http://www.trimira.net/

Animations

Identafi® Technology



Identafi® 3000 ultra Process



Screening Results



Training